A New Shield for Seniors: Health Canada Nods First RSV Vaccine for 60 and Up
Health Canada has granted approval for the first-ever vaccine targeting the respiratory syncytial virus (RSV) in adults aged 60 and older. The newly authorized vaccine, Arexvy, manufactured by GSK, is expected to offer substantial protection during the upcoming RSV season, despite a limited supply initially.
RSV is a highly contagious virus, typically resembling a common cold in most individuals. However, it can lead to more severe respiratory conditions, such as bronchiolitis and pneumonia, especially in vulnerable populations.
Seniors aged 60 and above are at a higher risk of experiencing severe illness and requiring hospitalization due to RSV infection.
Dr. Samir Sinha, the director of geriatrics at Sinai Health and University Health Network in Toronto, stated that ” It will be a game changer in significantly preventing severe illness and death, especially amongst older Canadians.
GSK’s Arexvy vaccine has shown promising results in a randomized clinical trial, indicating an 82% efficacy in preventing lower respiratory tract diseases caused by RSV in seniors compared to those who received a placebo.
For seniors with underlying medical conditions, the vaccine’s efficacy rises to an impressive 94% in preventing RSV-related illnesses.
“I think this vaccine will go a long way based on the results that are available … the vaccine appeared to be safe and appeared to provide very significant protection,” said Bogoch.
RSV Vaccine for Seniors 60+: Guidance Expected 2024
The medical community has long advocated for an RSV vaccine tailored to protect seniors, given the virus’s potential to cause severe health complications in this age group. With Health Canada’s approval, the country takes a significant step forward in safeguarding the well-being of older citizens during the RSV season.
The vaccine is administered as a single-dose injection, although further research is needed to determine whether a yearly booster will be necessary to maintain protection. Health Canada is expected to release national guidance on the vaccine in 2024.
Read Next: Back To The Office: White House Calls Federal Workers For Fall Return
Source: CBC
